Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

10.1K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.1K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.8K
3.8K
MicroRNAs01:22

MicroRNAs

4.2K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.2K
MicroRNAs01:22

MicroRNAs

24.5K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.5K
Ribosome Profiling02:24

Ribosome Profiling

4.3K
Ribosome profiling or ribo-sequencing is a deep sequencing technique that produces a snapshot of active translation in a cell. It selectively sequences the mRNAs protected by ribosomes to get an insight into a cell’s translation landscape at any given point in time.
Applications of ribosome profiling
Ribosome profiling has many applications, including in vivo monitoring of translation inside a particular organ or tissue type and quantifying new protein synthesis levels.
The technique...
4.3K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

13.8K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
13.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of trop-2 expression on the efficacy of trop-2-targeted antibody-drug conjugates in metastatic breast cancer: a systematic review and meta-analysis.

Journal of the National Cancer Institute·2026
Same author

Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER<sup>+</sup>HER2<sup>-</sup> breast cancer: a randomized phase 2 trial.

Nature medicine·2026
Same author

Variant-Specific Landscape of Mutual Exclusivity Among BRAF, EGFR, and KRAS Oncogenes Reveals Overlap With Functionally Antagonistic Mutant Pairs.

International journal of cancer·2026
Same author

World Health Organization classification of tumours of the breast 6th edition 2026.

Histopathology·2026
Same author

Descriptive study of stromal expression of CD73 in ductal carcinoma in situ of the breast.

Discover oncology·2026
Same author

Identification of an episignature for CHD3-related Snijders Blok-Campeau syndrome reveals heterogeneity in the CHARGE syndrome episignature: towards a better characterisation of chromatinopathies.

Genome medicine·2026

Related Experiment Video

Updated: Mar 15, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.3K

Portraying breast cancers with long noncoding RNAs.

Olivier Van Grembergen1, Martin Bizet2, Eric J de Bony1

  • 1Laboratory of Cancer Epigenetics, Faculty of Medicine, ULB-Cancer Research Center (U-CRC), Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium.

Science Advances
|September 13, 2016
PubMed
Summary

Long noncoding RNAs (lncRNAs) are implicated in breast cancer development. This study identified 215 dysregulated lncRNAs, revealing four breast cancer subtypes and potential therapeutic targets like CYTOR.

Keywords:
Epigeneticsbreast cancerlong non-coding RNA

More Related Videos

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.5K
Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization
06:01

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

7.1K

Related Experiment Videos

Last Updated: Mar 15, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.3K
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.5K
Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization
06:01

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

7.1K

Area of Science:

  • Genomics
  • Molecular Biology
  • Cancer Research

Background:

  • Long noncoding RNAs (lncRNAs) are increasingly recognized for their potential roles in cancer, but their specific functions in breast cancer remain largely undefined.
  • Understanding the lncRNA landscape is crucial for deciphering complex cancer biology and identifying novel therapeutic strategies.

Purpose of the Study:

  • To conduct a comprehensive genome-wide survey of lncRNAs in breast cancer to identify aberrantly expressed lncRNAs and their potential roles.
  • To classify breast tumors based on lncRNA expression profiles and correlate these subtypes with known molecular classifications and clinical outcomes.
  • To investigate the functional significance of specific lncRNAs, including CYTOR, in breast cancer progression and identify potential therapeutic targets.

Main Methods:

  • Genome-wide transcriptional profiling of 995 breast tissue samples to identify differentially expressed lncRNAs between tumors and normal tissues.
  • Unsupervised hierarchical clustering based on lncRNA expression to define novel breast cancer subtypes.
  • Multivariate analysis to identify lncRNAs prognostic of clinical outcome and coexpression analysis to infer lncRNA functions.
  • Functional validation of a specific lncRNA, CYTOR, focusing on its role in key cancer-related pathways and cellular processes.

Main Results:

  • Identified 215 aberrantly expressed lncRNAs in breast tumors compared to normal samples.
  • Discovered four distinct breast cancer subgroups based on lncRNA expression, which correlate with PAM50 mRNA-based subtypes.
  • Identified 210 lncRNAs as prognostic indicators of clinical outcome.
  • Associated specific lncRNAs with key molecular pathways, including PI3K, FGF, TGF-β, EGFR, and epithelial-to-mesenchymal transition (EMT).
  • Demonstrated that the lncRNA CYTOR regulates genes in the EGFR/mTOR pathway and is essential for cell proliferation, migration, and cytoskeleton organization.

Conclusions:

  • This study provides the most extensive analysis of the lncRNA landscape in breast cancer to date.
  • lncRNAs play diverse biological roles in breast cancer, influencing distinct molecular subtypes and clinical outcomes.
  • The identified lncRNAs, particularly CYTOR, represent promising avenues for further functional investigation and the development of novel therapeutic strategies for breast cancer.